Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry

Psychopharmacology, Год журнала: 2023, Номер 240(8), С. 1735 - 1745

Опубликована: Июнь 14, 2023

Abstract Rationale Cannabis-based medicinal products (CBMPs) have been identified as novel therapeutics for generalised anxiety disorder (GAD) based on pre-clinical models; however, there is a paucity of high-quality evidence their effectiveness and safety. Objectives This study aimed to evaluate the clinical outcomes patients with GAD treated dried flower, oil-based preparations, or combination both CBMPs. Methods A prospective cohort ( n = 302) enrolled in UK Medical Cannabis Registry prescribed oil flower-based CBMPs was performed. Primary were changes disorder-7 (GAD-7) questionnaires at 1, 3, 6 months compared baseline. Secondary single-item sleep quality scale (SQS) health-related life index (EQ-5D-5L) same time points. These assessed by paired t -tests. Adverse events line CTCAE (Common Terminology Criteria Events) v4.0. Results Improvements anxiety, observed each point p < 0.001). Patients receiving had improvements GAD-7 all points (1 month: difference −5.3 (95% CI −4.6 −6.1), 3 months: −5.5 −4.7 −6.4), −4.5 −3.2 −5.7)). Thirty-nine participants (12.9%) reported 269 adverse follow-up period. Conclusions Prescription those associated clinically significant an acceptable safety profile real-world setting. Randomised trials are required next step investigate efficacy

Язык: Английский

---

The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment

Addiction, Год журнала: 2023, Номер 118(7), С. 1282 - 1294

Опубликована: Фев. 8, 2023

Long-term harms of cannabis may be exacerbated in adolescence, but little is known about the acute effects adolescents. We aimed to (i) compare adolescent and adult users (ii) determine if cannabidiol (CBD) acutely modulates delta-9-tetrahydocannabinol (THC).Randomised, double-blind, placebo-controlled, crossover experiment. The experiment was registered on ClinicalTrials.gov (NCT04851392).Laboratory London, United Kingdom.Twenty-four adolescents (12 women, 16- 17-year-olds) 24 adults 26- 29-year-olds) who used 0.5-3 days/week were matched use frequency (mean = 1.5 days/week).We administered three weight-adjusted vaporised flower preparations: 'THC' (8 mg THC for 75 kg person); 'THC + CBD' CBD 'PLA' (matched placebo).Primary outcomes subjective 'feel drug effect'; verbal episodic memory (delayed prose recall); (iii) psychotomimetic effect (Psychotomimetic States Inventory).Compared with 'PLA', significantly (P < 0.001) increased effect' difference [MD] 6.3, 95% CI 5.3-7.2; MD 6.8, 6.0-7.7), impaired (MD -2.7, -4.1 -1.4; -2.9, -1.7) 7.8, 2.8-12.7; 10.8, 6.2-15.4). There no evidence that differed from their responses (interaction P ≥ 0.4). Bayesian analyses supported equivalent (Bayes factor [BF01 ] >3). modulated THC.Adolescent are neither more resilient nor vulnerable than psychotomimetic, memory-impairing or cannabis. Furthermore, adults, does not mitigate caused by delta-9-tetrahydocannabinol.

Язык: Английский

---

Supercritical Carbon Dioxide Technology for Recovering Valuable Phytochemicals from Cannabis sativa L. and Valorization of Its Biomass for Food Applications

Molecules, Год журнала: 2023, Номер 28(9), С. 3849 - 3849

Опубликована: Май 1, 2023

Supercritical carbon dioxide (CO2) extraction techniques meet all-new consumer market demands for health-promoting phytochemical compound-rich extracts produced from green and sustainable technology. In this regard, review is dedicated to discussing the promise of integrating high-pressure CO2 technologies into Cannabis sativa L. processing chain valorize its valuable pharmaceutical properties food biomass. To do this, cannabis plant, cannabinoids, endocannabinoid system were reviewed understand their therapeutic side effects. The supercritical fluid (SFE) technique was presented as a smart alternative producing bioproducts. impact SFE operating conditions on compound examined aerial parts (inflorescences, stems, leaves), seeds, byproducts. Furthermore, opportunities using non-thermal biomass addressed industrial hemp valorization, focusing biorefinery simultaneously produce cannabidiol new ingredients applications plant-based products.

Язык: Английский

---

Cannabidiol attenuates periodontal inflammation through inhibiting TLR4/NF‐κB pathway

Journal of Periodontal Research, Год журнала: 2023, Номер 58(4), С. 697 - 707

Опубликована: Май 4, 2023

Abstract Background and Objective Periodontitis is a chronic inflammatory disease involving soft hard tissue destruction in the periodontal region. Cannabidiol (CBD) natural compound isolated from cannabis, which has effect of inhibiting inflammation. However, role CBD periodontitis remains unclear. The aim this study was to investigate anti‐inflammatory effects osteoprotective actions its molecular mechanisms. Materials Methods After establishing rat model by ligatures, specimens were processed for morphometric analysis Micro‐CT. gingival tissues collected, levels TNF‐α, IL‐1β, TLR4 measured enzyme‐linked immunosorbent assay. LPS used induce response human ligament cells (hPDLCs) vitro. QPCR western blot carried out detect expression related cytokines signaling pathways. Results significantly inhibits bone loss experimental models. downregulated pro‐inflammatory mediator decrease protein expression. Overexpression TNF‐α caused hPDLCs. inactivated TLR4/NF‐κB pathway TLR‐4 p65 NF‐κB phosphorylation. can be considered as therapeutic agent periodontitis. Conclusion Our demonstrated that attenuates ligature‐induced rats LPS‐induced inflammation hPDLCs activation. It indicates topical application effective treating

Язык: Английский

---

Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy

Pharmaceutics, Год журнала: 2023, Номер 15(2), С. 554 - 554

Опубликована: Фев. 7, 2023

In cancer patients, chronic paclitaxel (PTX) treatment causes excruciating pain, limiting its use in chemotherapy. The neuroprotective potential of synthetic cannabidiol (CBD) and CBD formulated extracellular vesicles (CBD-EVs) isolated from human umbilical cord derived mesenchymal stem cells was investigated C57BL/6J mice with PTX-induced neuropathic pain (PIPN). particle size EVs CBD-EVs, surface roughness, nanomechanical properties, stability, release studies were all investigated. To develop neuropathy mice, PTX (8 mg/kg, i.p.) administered every other day (four doses). terms decreasing mechanical thermal hypersensitivity, CBD-EVs superior to or alone (p < 0.001). significantly reduced mitochondrial dysfunction dorsal root ganglions spinal homogenates PTX-treated animals by modulating the AMPK pathway Studies inhibiting 5HT1A receptors found that did not influence neurobehavioral function PIPN. Based on these results, we hypothesize mitigated PIPN function.

Язык: Английский

---